- Clinical-stage vaccine innovation company Vaxcyte (NASDAQ:PCVX) priced of an underwritten public offering of ~10.19M shares and pre-funded warrants to purchase ~2.43M shares.
- The shares of common stock are being sold at a public offering price of $103.00 per share.
- Gross proceeds are expected to be ~$1.3B.
- The offering is expected to close on September 6, 2024.
